VRAX
NASDAQVirax Biolabs Group Limited
News · 26 weeks23-17%
2025-10-262026-04-19
Mix1390d
- Insider6(46%)
- SEC Filings4(31%)
- Other3(23%)
Latest news
25 items- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersVirax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its balance sheet strength, debt-free position, recent financing and operational progress.LONDON, April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immunology research and diagnostics, today published a shareholder letter from Chief Executive Officer James Foster and released an updated investor presentation. Together, these materials outline Virax's current strategic and commercial framework and the m
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- INSIDERSEC Form 3 filed by new insider Haight Nelson M3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- PRVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationLONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (
- INSIDERSEC Form 3 filed by new insider Mccracken Nigel William3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- INSIDERSEC Form 3 filed by new insider Foster James Alexander Cunliffe3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- INSIDERSEC Form 3 filed by new insider Norton Evan Michael3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- INSIDERSEC Form 3 filed by new insider Davis Jason3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- INSIDERSEC Form 3 filed by new insider Miller Iain David3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Virax Biolabs Group LimitedSCHEDULE 13G - Virax Biolabs Group Ltd (0001885827) (Subject)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 424B3 filed by Virax Biolabs Group Limited424B3 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form EFFECT filed by Virax Biolabs Group LimitedEFFECT - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form F-3 filed by Virax Biolabs Group LimitedF-3 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form D filed by Virax Biolabs Group LimitedD - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Group Limited Announces Closing of $5 Million Private PlacementExtends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceed
- PRVirax Biolabs Group Limited Announces $5 Million Private PlacementLONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred investment option in a private placement . The prefer
- PRVirax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to ShareholdersVirax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series of recent clinical and operational milestones over the past 12 months. LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors.
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection SyndromesLONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that it has successfully completed patient recruitment for its United Kingdom-based, multi-centre clinical study evaluating the performance of the ViraxImmune™ assay in detecting T cell dysfunction in Post-Acute Infection Syndromes ("PAIS"), including Long COVID, post-treatment Lyme disease ("PTLD"), and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome ("ME/CFS").
- PRVirax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberLONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection and diagnostics, today announced it has signed a Research Services Agreement ("RSA") with Emory University's Center for the Advancement of Diagnostics for a Just Society ("ADJUST Center") to conduct clinical studies of ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, beginning with post-acute sequelae of SARS-CoV-2 ("PASC"), commonly known as long COVID.
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)